Human Genome (HGSI) Trades Well Above GSK Offer, Other Biotechs See Action
Tweet Send to a FriendGet Alerts HGSI Hot Sheet
Trade HGSI Now!
Shares of Human Genome Sciences Inc. (Nasdaq: HGSI) are trading beyond Glaxo's (NYSE: GSK) rejected $13 per share bid on speculation of a higher bid.
Human Genome last traded at $14.50, up 103 percent.
The news is also boosting other biotech stocks on M&A hopes:
Dendreon Corp. (Nasdaq: DNDN) is up 10%
VIVUS Inc. (Nasdaq: VVUS) is indicated higher.
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) is indicated higher
InterMune Inc. (Nasdaq: ITMN) is indicated higher
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Human Genome last traded at $14.50, up 103 percent.
The news is also boosting other biotech stocks on M&A hopes:
Dendreon Corp. (Nasdaq: DNDN) is up 10%
VIVUS Inc. (Nasdaq: VVUS) is indicated higher.
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) is indicated higher
InterMune Inc. (Nasdaq: ITMN) is indicated higher
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Tesoro Corporation (TSO) May Take Ownership of BP Carson in Early June - Reuters
- Can AMD (AMD) Shake Off the Goldman Downgrade?
- Tableau Software (DATA) IPO Surges Higher
Create E-mail Alert Related Categories
Rumors, Trader Talk
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
